Published in Vaccine Weekly, January 24th, 2007
Known as Zostavax, the vaccine is used in adults age 60 and older and reduces the incidence of shingles by half and pain and discomfort by nearly two-thirds according to Merck research.
"This vaccine helps prevent an illness that affects many older Americans and often results in significant pain," said Jeff Heatherington, president. "While experts worried that partial insurance coverage of Zostavax might slow its acceptance, FamilyCare is committed to offering our valued members 100% coverage for a medical breakthrough vaccine that helps prevent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2007-01-24)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.